Anti-Depression Medication: Current Landscape and Product Development Trends

Alison Wakeford, PhD, Scientist, Allucent Marcus S. Delatte, PhD, VP Regulatory Strategy, Allucent Background According to the World Health Organization, depression is a common mood disorder, affecting approximately 280 million people globally.1 Depression is characterized by persistent feelings of sadness and loss of interest, occurs across almost all age groups, and manifests in various forms […]

Rare Central Nervous System Disease Trials

Precision medicine offers the promise to treat a variety of conditions, especially rare diseases, with targeted approaches. But developing more personalized medicines can introduce new complexities in the clinical trial process, which can hold back drug developers on the road to commercialization. Find out the factors that make rare neurological diseases a prime target for precision […]

Big passion for small biotech and its potential to address complex diseases

Originally published by Teresa Nunes is responsible for overseeing the activities of the medical affairs and pharmacovigilance teams at the specialized Clinical Research Organization (CRO) leader, Allucent. Here she discusses what drives her passion for helping small and mid-sized biotechnology companies bring new therapies to light for patients around the world – and why she’s […]

Developing CNS Neurotherapeutics with Cerebrospinal PK/PD Clinical Studies

Neurological diseases affect the brain, spinal cord, and peripheral nervous system. They range from diseases that affect large populations such as Alzheimer’s, epilepsy, stroke, Parkinson’s, and multiple sclerosis to rare and genetically inherited diseases like Huntington’s, lysosomal storage diseases, and Amyotrophic Lateral Sclerosis. With more than 2 billion people affected worldwide (and rising), neurological diseases […]